Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75

Immunoglobulin light chain (AL) amyloidosis is a disorder driven by clonal plasma cells or B cells producing amyloidogenic light chain protein that deposits in various organs leading to organ dysfunction. Like multiple myeloma it is more common in the elderly, with a median age at presentation of 64. [1,2] Autologous stem cell transplantation (ASCT)has been utilized in AL amyloidosis for over two decades and although early experience was marred by high rates of early mortality, advances in understanding of high risk features optimized selection criteria and have helped improve safety and efficacy of this therapy.

Source: Biology of Blood and Marrow Transplantation - June 19, 2018 Category: Hematology Authors: M Hasib Sidiqi, Mohammed A. Aljama, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, Angela Dispenzieri, David Dingli, Nelson Leung, Wilson I. Gonsalves, Prashant Kapoor, Taxiarchis V. Kourelis, William J. Hogan, Shaji K. Kumar, Morie A. Gert Source Type: research